Idera Pharmaceuticals Presents Data in Preclinical Models of Lymphoma on IMO ... MarketWatch (press release) The presentation by Idera scientists, entitled "IMO-4200, a novel TLR7 and TLR8 dual agonist, enhances antitumor effect of ofatumumab, rituximab and cytotoxics in preclinical models of hematological malignancies", abstract number 3724, was made at the ... |
